New cocktail of drugs shows promise for tough bile duct cancer
NCT ID NCT07432568
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors. The trial will enroll 30 participants and measure how many respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal irinotecan, 5-fluorouracil, leucovorin, lenvatinib, and a PD-1 inhibitor
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with advanced bile duct cancer, potentially shrinking tumors and extending survival.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet proven to be better than current treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable